Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
888 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01513187 | Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 53 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 |
| NCT00112840 | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2022 | clinicaltrials |
| NCT01399918 | Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 57 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT01566747 | Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5 | completed | Phase 2 | 43 | Cancer Trials IrelandNETWORK | 2 | Dec 23, 2021 | clinicaltrials |
| NCT03136627 | Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC | completed | Phase 1 / Phase 2 | 28 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT03430895 | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | completed | Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT00550277 | LBH589 Treatment for Refractory Clear Cell Renal Carcinoma | completed | Phase 2 | 20 | SCRI Development Innovations, LLCOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT03520231 | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases | completed | Phase 2 | 6 | University Health Network, TorontoOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT04555343 | Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention | completed | Phase 1 / Phase 2 | 14 | Fraser HealthOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | completed | Phase 2 | 5 | Seagen Inc.INDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT00318643 | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 27 | Halozyme TherapeuticsINDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT03013335 | Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen(NIVOREN) | completed | Phase 2 | 730 | UNICANCEROTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT01392183 | Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) | completed | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT03339219 | A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma | completed | Phase 2 | 35 | TakedaINDUSTRY | 1 | Sep 20, 2021 | clinicaltrials |
| NCT02599779 | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients(OZM-065) | completed | Phase 2 | 4 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01896271 | High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer | completed | Phase 2 | 30 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT00694915 | Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder(STCC) | completed | Phase 2 | 122 | Cadila PharnmaceuticalsINDUSTRY | 1 | Aug 17, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT01024920 | Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. | completed | Phase 2 | 99 | Boehringer IngelheimINDUSTRY | 5 | Jul 19, 2021 | clinicaltrials |
| NCT02989714 | Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer | completed | Phase 1 / Phase 2 | 13 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT03494816 | Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion(NAXIVA) | completed | Phase 2 | 24 | Scottish Clinical Trials Research UnitOTHER | 1 | Jun 30, 2021 | clinicaltrials |
| NCT00118040 | Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02009332 | Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | Aadi Bioscience, Inc.INDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT02118337 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 97 | MedImmune LLCINDUSTRY | 6 | Jun 1, 2021 | clinicaltrials |
| NCT03354884 | caBozantinib in cOllectiNg ductS Renal Cell cArcInoma(BONSAI) | completed | Phase 2 | 23 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT01827943 | Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer(VESTOR) | completed | Phase 2 | 54 | Institut BergoniéOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT03463681 | A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma(BREAKPOINT) | completed | Phase 2 | 49 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 26, 2021 | clinicaltrials |
| NCT02127710 | A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC) | completed | Phase 2 | 111 | AstraZenecaINDUSTRY | 4 | Apr 19, 2021 | clinicaltrials |
| NCT02365818 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure(BOND2) | completed | Phase 2 | 66 | CG Oncology, Inc.INDUSTRY | 1 | Apr 14, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT00121251 | Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT03065179 | SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients(RADVAX) | completed | Phase 2 | 29 | University of Texas Southwestern Medical CenterOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT02363751 | Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)(BEVABEL) | completed | Phase 2 | 36 | UNICANCEROTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00056095 | Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 57 | UNICANCEROTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT00827359 | Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT00003683 | Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 40 | UNICANCEROTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00006111 | Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract | completed | Phase 2 | 53 | UNICANCEROTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00541008 | Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer | completed | Phase 2 | 92 | UNICANCEROTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01835158 | Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | completed | Phase 2 | 157 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2021 | clinicaltrials |
| NCT00664326 | A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC | completed | Phase 2 | 49 | BayerINDUSTRY | 6 | Jan 29, 2021 | clinicaltrials |
| NCT04184232 | Treatment of Recurrent Bladder Cancer With Dendritic Cells | completed | Phase 2 | 17 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusOTHER_GOV | 1 | Jan 22, 2021 | clinicaltrials |
| NCT02197897 | Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors(BCTamoxifen) | completed | Phase 2 | 15 | Baylor College of MedicineOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT02082210 | A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | completed | Phase 1 / Phase 2 | 97 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01798446 | A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus | completed | Phase 2 | 41 | Seoul National University HospitalOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03066427 | Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.(INMUNOSUN) | completed | Phase 2 | 23 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT02788201 | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 6, 2020 | clinicaltrials |
| NCT01297244 | A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 105 | AVEO Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 27, 2020 | clinicaltrials |
| NCT00003930 | Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | completed | Phase 1 / Phase 2 | 84 | Radiation Therapy Oncology GroupNETWORK | 2 | Oct 20, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Mar 10, 2022source: clinicaltrials